Cambridge Healthtech Institute’s 12th Annual

Advancing Bispecific Antibodies and Combination Therapy to the Clinic

Creating the Killer Combo

MAY 14 - 15, 2024 ALL TIMES EST


Bispecific antibodies continue to dominate the biologics landscape and their advancement to the clinic is showing extraordinary promise. The application of innovative approaches through precise activation, gating, and masking approaches is giving better control of targeting and efficacy. Insights into how these constructs behave in vivo and how to mitigate toxicity and off-target effects will be reviewed from preclinical and clinical studies. The 12th Annual Advancing Bispecific Antibodies and Combination Therapy to the Clinic conference at the PEGS Boston Summit brings together the leading researchers in the industry to strategize on the safety and efficacy of new constructs, review the latest clinical results, and expand their use into areas beyond oncology.

Scientific Advisory Board
   Frank Comer, PhD, Director, Tumor Targeted Delivery, Early Oncology Discovery, AstraZeneca
   Eric Smith, PhD, Senior Director, Bispecifics, Regeneron Pharmaceuticals, Inc.
   Nathan D. Trinklein, PhD, Co-Founder and President, Rondo Therapeutics

 






For more details on the conference, please contact:

Christina Lingham

Executive Director, Conferences and Fellow

Cambridge Healthtech Institute

Phone: 508-813-7570

Email: clingham@healthtech.com

 

For sponsorship information, please contact:

Companies A-K

Jason Gerardi

Senior Manager, Business Development

Cambridge Healthtech Institute

Phone: 781-972-5452

Email: jgerardi@healthtech.com

 

Companies L-Z

Ashley Parsons

Manager, Business Development

Cambridge Healthtech Institute

Phone: 781-972-1340

Email: ashleyparsons@healthtech.com


Register Now

View By:


Premier Sponsors

  Evitria_ag_companyLogo FairJourneyBiologics Integral-Molecular_NEWOmniAb   UnchainedLabs